Biologic treatments for RA carry similar infection risk

July 28, 2014
Biologic treatments for RA carry similar infection risk
The risk of hospitalized bacterial infections in older rheumatoid arthritis patients is similar for rituximab or abatacept compared to etanercept, although it is higher for infliximab, according to a study published in the July issue of Arthritis Care & Research.

(HealthDay)—The risk of hospitalized bacterial infections in older rheumatoid arthritis (RA) patients is similar for rituximab or abatacept compared to etanercept, although it is higher for infliximab, according to a study published in the July issue of Arthritis Care & Research.

Jeffrey R. Curtis, M.D., from the University of Alabama at Birmingham, and colleagues utilized 1998 to 2011 data from the U.S. Veterans Health Administration to identify RA patients initiating , abatacept, or anti-tumor necrosis factor (anti-TNF) therapy. The authors sought to assess the comparative risk of hospitalized infection associated with anti-TNF and non-anti-TNF biologic agents.

The researchers found that 3,152 unique RA patients (mean age, 60 years; 87 percent male) had 4,158 biologic treatment episodes of rituximab (596 initiations), abatacept (451 initiations), and anti-TNF agents (3,111 initiations). For rituximab, the hospitalized infection rate was 4.4 per 100 person-years; rates were 2.8 for abatacept and 3.0 for anti-TNF. The adjusted rates of hospitalized infection were similar for adalimumab (hazard ratio [HR], 1.4; 95 percent confidence interval [CI], 0.9 to 2.2), abatacept (HR, 1.1; 95 percent CI, 0.6 to 2.1), or rituximab (HR, 1.4; 95 percent CI, 0.8 to 2.6), compared to etanercept, although it was increased for (HR, 2.3; 95 percent CI,, 1.3 to 4.0).

"In older, predominantly male U.S. veterans with RA, the risk of hospitalized bacterial infections associated with rituximab or abatacept was similar to etanercept," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further: Arthritis patients taking newer treatments do not have an overall increased cancer risk

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Obesity is a risk factor for poor remission rates in RA

July 6, 2012

(HealthDay) -- For patients with long-standing rheumatoid arthritis treated with anti-tumor necrosis factor-α (anti-TNFα) therapies, obesity is related to poor remission rates, according to a study published online ...

Recommended for you

Zika virus may persist in the vagina days after infection

August 25, 2016

The Zika virus reproduces in the vaginal tissue of pregnant mice several days after infection, according to a study by Yale researchers. From the genitals, the virus spreads and infects the fetal brain, impairing fetal development. ...

In sub-Saharan Africa, cancer can be an infectious disease

August 26, 2016

In 1963, Irish surgeon Denis Parson Burkitt airmailed samples of an unusual jaw tumor found in Ugandan children to his colleague, Anthony Epstein, at Middlesex Hospital in London. Epstein, an expert in chicken viruses and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.